These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Rituximab (MABTHERA) and severe polyangiitis. An option for patients informed of the uncertainties. Prescrire Int; 2015 Jun 06; 24(161):145-8. PubMed ID: 26436161 [Abstract] [Full Text] [Related]
7. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR, European Vasculitis Study Group. N Engl J Med; 2010 Jul 15; 363(3):211-20. PubMed ID: 20647198 [Abstract] [Full Text] [Related]
8. Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term follow-up data. de Joode AAE, Sanders JSF, Puéchal X, Guillevin LP, Hiemstra TF, Flossmann O, Rasmussen N, Westman K, Jayne DR, Stegeman CA. Rheumatology (Oxford); 2017 Nov 01; 56(11):1894-1901. PubMed ID: 28977502 [Abstract] [Full Text] [Related]
9. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. Geetha D, Specks U, Stone JH, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Fessler BJ, Ding L, Tchao NK, Ikle D, Jepson B, Brunetta P, Fervenza FC, Rituximab for ANCA-Associated Vasculitis Immune Tolerance Network Research Group. J Am Soc Nephrol; 2015 Apr 01; 26(4):976-85. PubMed ID: 25381429 [Abstract] [Full Text] [Related]
10. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Unizony S, Villarreal M, Miloslavsky EM, Lu N, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CM, St Clair EW, Ikle D, Tchao NK, Ding L, Brunetta P, Choi HK, Monach PA, Fervenza F, Stone JH, Specks U, RAVE-ITN Research Group. Ann Rheum Dis; 2016 Jun 01; 75(6):1166-9. PubMed ID: 26621483 [Abstract] [Full Text] [Related]
14. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. Terrier B, Pagnoux C, Perrodeau É, Karras A, Khouatra C, Aumaître O, Cohen P, Decaux O, Desmurs-Clavel H, Maurier F, Gobert P, Quémeneur T, Blanchard-Delaunay C, Bonnotte B, Carron PL, Daugas E, Ducret M, Godmer P, Hamidou M, Lidove O, Limal N, Puéchal X, Mouthon L, Ravaud P, Guillevin L, French Vasculitis Study Group. Ann Rheum Dis; 2018 Aug 01; 77(8):1150-1156. PubMed ID: 29724729 [Abstract] [Full Text] [Related]
15. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Jayne D, Blockmans D, Luqmani R, Moiseev S, Ji B, Green Y, Hall L, Roth D, Henderson RB, Merkel PA, BREVAS Study Collaborators. Arthritis Rheumatol; 2019 Jun 01; 71(6):952-963. PubMed ID: 30666823 [Abstract] [Full Text] [Related]
19. Different responses to treatment across classified diseases and severities in Japanese patients with microscopic polyangiitis and granulomatosis with polyangiitis: a nationwide prospective inception cohort study. Sada KE, Yamamura M, Harigai M, Fujii T, Takasaki Y, Amano K, Fujimoto S, Muso E, Murakawa Y, Arimura Y, Makino H, Research Committee on Intractable Vasculitides, the Ministry of Health, Labour and Welfare of Japan. Arthritis Res Ther; 2015 Nov 02; 17():305. PubMed ID: 26525413 [Abstract] [Full Text] [Related]
20. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. Hiemstra TF, Walsh M, Mahr A, Savage CO, de Groot K, Harper L, Hauser T, Neumann I, Tesar V, Wissing KM, Pagnoux C, Schmitt W, Jayne DR, European Vasculitis Study Group (EUVAS). JAMA; 2010 Dec 01; 304(21):2381-8. PubMed ID: 21060104 [Abstract] [Full Text] [Related] Page: [Next] [New Search]